DK3202766T3 - Isoxazolderivat som muteret isocitratdehydrogenase 1-inhibitor - Google Patents
Isoxazolderivat som muteret isocitratdehydrogenase 1-inhibitor Download PDFInfo
- Publication number
- DK3202766T3 DK3202766T3 DK15845549.3T DK15845549T DK3202766T3 DK 3202766 T3 DK3202766 T3 DK 3202766T3 DK 15845549 T DK15845549 T DK 15845549T DK 3202766 T3 DK3202766 T3 DK 3202766T3
- Authority
- DK
- Denmark
- Prior art keywords
- muterated
- inhibitor
- isocitrate dehydrogenase
- isoxazole derivative
- isoxazole
- Prior art date
Links
- 229940123392 Isocitrate dehydrogenase 1 inhibitor Drugs 0.000 title 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical class C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014203475 | 2014-10-01 | ||
| JP2015116774 | 2015-06-09 | ||
| PCT/JP2015/077916 WO2016052697A1 (ja) | 2014-10-01 | 2015-10-01 | 変異型イソクエン酸デヒドロゲナーゼ１阻害剤としてのイソキサゾール誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3202766T3 true DK3202766T3 (da) | 2020-03-23 |
Family
ID=55630718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15845549.3T DK3202766T3 (da) | 2014-10-01 | 2015-10-01 | Isoxazolderivat som muteret isocitratdehydrogenase 1-inhibitor |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US10040791B2 (da) |
| EP (1) | EP3202766B1 (da) |
| JP (1) | JP6087033B2 (da) |
| KR (1) | KR102440429B1 (da) |
| CN (1) | CN106795146B (da) |
| AU (1) | AU2015325279B2 (da) |
| BR (1) | BR112017006425B8 (da) |
| CA (1) | CA2963359C (da) |
| CO (1) | CO2017003969A2 (da) |
| CY (1) | CY1122891T1 (da) |
| DK (1) | DK3202766T3 (da) |
| ES (1) | ES2779305T3 (da) |
| HR (1) | HRP20200395T1 (da) |
| HU (1) | HUE048997T2 (da) |
| IL (1) | IL251305B (da) |
| LT (1) | LT3202766T (da) |
| MX (1) | MX2017003782A (da) |
| PH (1) | PH12017500530B1 (da) |
| PL (1) | PL3202766T3 (da) |
| PT (1) | PT3202766T (da) |
| RS (1) | RS60064B1 (da) |
| RU (1) | RU2692782C2 (da) |
| SG (1) | SG11201702389XA (da) |
| SI (1) | SI3202766T1 (da) |
| SM (1) | SMT202000275T1 (da) |
| WO (1) | WO2016052697A1 (da) |
| ZA (1) | ZA201703013B (da) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017019429A1 (en) * | 2015-07-27 | 2017-02-02 | Eli Lilly And Company | 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds and theit use as mutant idh1 inhibitors |
| JP6682043B2 (ja) * | 2016-06-06 | 2020-04-15 | イーライ リリー アンド カンパニー | 変異体ｉｄｈ１阻害剤 |
| WO2018010142A1 (en) * | 2016-07-14 | 2018-01-18 | Shanghai Meton Pharmaceutical Co., Ltd | Iso-citrate dehydrogenase (idh) inhibitor |
| JP2020535112A (ja) * | 2017-08-01 | 2020-12-03 | ドイッチェス・クレープスフォルシュングスツェントルムＤｅｕｔｓｃｈｅｓ Ｋｒｅｂｓｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ | Ｍｉｄｈ１阻害剤とｄｎａ低メチル化剤（ｈｍａ）との組合せ |
| WO2019146129A1 (ja) * | 2018-01-29 | 2019-08-01 | 富士フイルム株式会社 | イソクエン酸デヒドロゲナーゼ変異を有する腫瘍に対する医薬組成物および抗腫瘍剤ならびにその利用 |
| PT4010331T (pt) | 2019-08-08 | 2024-01-08 | Servier Lab | Um método de preparação do ivosidenib e de um seu intermediário |
| US20240139205A1 (en) | 2020-03-05 | 2024-05-02 | Universite De Lausanne | Modulators of aralar for treating neurological disorders |
| US20230270814A1 (en) * | 2020-07-21 | 2023-08-31 | Daiichi Sankyo Company, Limited | Combination pharmaceutical of temozolomide and mutant idh1 enzyme inhibitor |
| US20230382856A1 (en) * | 2020-10-30 | 2023-11-30 | Daiichi Sankyo Company, Limited | Method of producing 3-methyl-4-halo-indole derivative |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3194811A (en) | 1963-09-05 | 1965-07-13 | Merck & Co Inc | Aroyl-benzindolyl acids |
| AU678186B2 (en) | 1992-10-23 | 1997-05-22 | Merck Sharp & Dohme Limited | Dopamine receptor subtype ligands |
| WO1994024095A1 (en) | 1993-04-16 | 1994-10-27 | Abbott Laboratories | Immunosuppressive agents |
| GB2284600A (en) * | 1994-01-21 | 1995-06-14 | Shell Int Research | Herbicidal 3-(hetero)aryl-4-acylisoxazole compositions and compounds |
| KR101166749B1 (ko) * | 2003-02-11 | 2012-07-27 | 베르날리스(캠브리지)리미티드 | 열쇼크 단백질 저해제로서의 이소옥사졸 화합물 |
| WO2006031631A1 (en) * | 2004-09-10 | 2006-03-23 | Syngenta Limited | Substituted isoxazoles as fungicides |
| CN103097340B (zh) * | 2010-07-16 | 2018-03-16 | 安吉奥斯医药品有限公司 | 治疗活性组合物及其使用方法 |
| EP2691391A4 (en) | 2011-03-29 | 2014-09-10 | Broad Inst Inc | COMPOUNDS AND METHODS OF TREATING DISORDERS MEDIATED BY ISOCITRATE DEHYDROGENASE |
| CN102827170A (zh) * | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| CN102827073A (zh) * | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| MX342326B (es) * | 2011-09-27 | 2016-09-26 | Novartis Ag | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante. |
| US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
| ES2698625T3 (es) | 2012-01-19 | 2019-02-05 | Agios Pharmaceuticals Inc | Compuestos terapéuticamente activos y sus métodos de uso |
-
2015
- 2015-10-01 LT LTEP15845549.3T patent/LT3202766T/lt unknown
- 2015-10-01 JP JP2016552161A patent/JP6087033B2/ja active Active
- 2015-10-01 ES ES15845549T patent/ES2779305T3/es active Active
- 2015-10-01 MX MX2017003782A patent/MX2017003782A/es unknown
- 2015-10-01 RS RS20200290A patent/RS60064B1/sr unknown
- 2015-10-01 WO PCT/JP2015/077916 patent/WO2016052697A1/ja not_active Ceased
- 2015-10-01 AU AU2015325279A patent/AU2015325279B2/en active Active
- 2015-10-01 CA CA2963359A patent/CA2963359C/en active Active
- 2015-10-01 HR HRP20200395TT patent/HRP20200395T1/hr unknown
- 2015-10-01 PT PT158455493T patent/PT3202766T/pt unknown
- 2015-10-01 RU RU2017114005A patent/RU2692782C2/ru active
- 2015-10-01 SM SM20200275T patent/SMT202000275T1/it unknown
- 2015-10-01 US US15/516,362 patent/US10040791B2/en active Active
- 2015-10-01 SG SG11201702389XA patent/SG11201702389XA/en unknown
- 2015-10-01 BR BR112017006425A patent/BR112017006425B8/pt active IP Right Grant
- 2015-10-01 SI SI201531109T patent/SI3202766T1/sl unknown
- 2015-10-01 PL PL15845549T patent/PL3202766T3/pl unknown
- 2015-10-01 EP EP15845549.3A patent/EP3202766B1/en active Active
- 2015-10-01 CN CN201580050809.8A patent/CN106795146B/zh active Active
- 2015-10-01 HU HUE15845549A patent/HUE048997T2/hu unknown
- 2015-10-01 DK DK15845549.3T patent/DK3202766T3/da active
- 2015-10-01 KR KR1020177011877A patent/KR102440429B1/ko active Active
-
2017
- 2017-03-21 IL IL251305A patent/IL251305B/en active IP Right Grant
- 2017-03-22 PH PH12017500530A patent/PH12017500530B1/en unknown
- 2017-04-24 CO CONC2017/0003969A patent/CO2017003969A2/es unknown
- 2017-04-28 ZA ZA2017/03013A patent/ZA201703013B/en unknown
-
2020
- 2020-03-13 CY CY20201100221T patent/CY1122891T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3447050T3 (da) | Pyridin-2(1h)-on-quinolinderivater som mutant-isocitrat dehydrogenaseinhibitorer | |
| DK3464271T3 (da) | Pyrazolderivater som plasma-kallikreininhibitorer | |
| DK3277677T3 (da) | 1-cyano-pyrrolidinforbindelser som usp30-hæmmere | |
| CL2016002736A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| DK3302448T3 (da) | Erstattede heterocyclylafledninger som cdk-inhibitore | |
| DK3105218T3 (da) | Cyclopropylaminer som lsd1-inhibitorer | |
| DK3105226T3 (da) | Cyclopropylaminer som lsd1-inhibitorer | |
| DK3371190T3 (da) | Heterocykliske forbindelser som pi3k-gamma-inhibitorer | |
| DK3094631T4 (da) | Pyrimidinyloxybenzenderivater som herbicider | |
| DK3357919T3 (da) | Aromatiske heterocykliske forbindelser som antiinflammatoriske forbindelser | |
| CU20160125A7 (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
| DK3233843T3 (da) | Isoxazol-hydraxamsyreforbindelser som LPXC-hæmmere | |
| DK3239143T3 (da) | Biarylderivat som gpr120-agonist | |
| DK3183051T3 (da) | Væske-til-luftmembranenergivekslere | |
| HUE048997T2 (hu) | Izoxazol származék mutáns izocitrát dehidrogenáz 1 inhibitorként | |
| DK3116475T3 (da) | Dopa-decarboxylasehæmmersammensætninger | |
| DK3341379T3 (da) | EZH2-hæmmere | |
| DK3114120T3 (da) | Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere | |
| IL249443B (en) | Biomarkers for response to ezh2 inhibitors | |
| IL250038A0 (en) | 4,5 - dehydroisoxazole derivatives used as nampt inhibitors | |
| DK3319970T3 (da) | Pyrido-oxazinonderivater som tnap-hæmmere | |
| DK3186227T3 (da) | Nye sulfonylaminobenzamid-forbindelser som anthelmintika | |
| DK3233839T3 (da) | Heterocyclylkoblede imidazopyridazinderivater som pi3k-beta-inhibitorer | |
| HUE042119T2 (hu) | Aminoészter-származékok | |
| DK3138840T3 (da) | Thiadiazolidin-derivat som anti-enterovirus 71 |